ArticleCureus2026
Valproic Acid and Famotidine Drug-Drug Interaction: Report of a Pediatric Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valproic acid is a broad-spectrum anticonvulsant medication that is used to treat multiple neurologic and psychiatric disorders such as epilepsy, bipolar disorder, schizophrenia, and migraine prophylaxis. Famotidine is an antacid used for various gastrointestinal conditions, including gastric and duodenal ulcers and gastroesophageal acid reflux disease (GERD). Acute ingestion of famotidine was found to inhibit anticonvulsant action and increase brain concentrations relative to free plasma levels in a mouse model. While they are not known to interact with one another, one of their proposed metabolisms is through the same CYP450 enzyme. However, a drug-drug interaction between valproic acid and famotidine, or this interaction causing toxicity in a child, is extremely rare. A 10-year-old male with a past medical history of bipolar disorder, posttraumatic stress disorder, and anxiety presented to a community emergency department (ED) with acute altered mental status and increasing somnolence. Routinely taking valproic acid, he had started prescription famotidine two days prior. In the ED, his valproic acid levels were six times the upper limit of normal with associated elevated creatinine and hypocalcemia. Later, hyperammonemia developed. He was ultimately treated with L-carnitine, lactulose, and meropenem as well as admitted to the pediatric intensive care unit (PICU) with normalization of lab values and complete resolution of his neurologic symptoms after 29 hours. This case describes an extremely rare drug-to-drug interaction of valproic acid and famotidine leading to acute altered mental status in a pediatric patient. While causality cannot be established from a single case, clinicians should consider this potential interaction when new medications are added to a stable valproic acid regimen, as these two medications are commonly prescribed in both adults and children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.